Axentis boasts strength in presentation

Swiss firm Axentis Pharma is to present its recent successes in developing and financing a new therapeutic formulation for treating  chronic lung disease at the 2nd Annual European Life Science CEO Forum  in Zurich.

Chief operating officer Susanne Acklin said: "our lead product  ARB-CF0223 - a liposomal formulation of tobramycin, delivered directly  to the site of infection via standard nebulizers - produced very  satisfying data from a Phase I trial; we initiated a Phase II trial and  a subsequent capital increase was well received - and subscribed - by  our existing private investors."

Chief executive Helmut Brunar added: "ARB-CF0223 - also known as  Fluidosome tobramycin - is expected to generate a peak annual turnover  of approximately 100.0 million euros ($128.2 million) within five years  of market launch."